| Literature DB >> 12789624 |
Abstract
Bristol-Myers Squibb is developing BMS-214662, a farnesyl transferase inhibitor, for the potential treatment of cancer. By October 2000, preclinical investigations were ongoing in Japan. By February 2001, the drug was in phase II trials in the US for pancreatic, head and neck, lung and colorectal cancers.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12789624
Source DB: PubMed Journal: IDrugs ISSN： 1369-7056